Sartorius Stedim Biotech, a supplier for the biopharmaceutical industry, has signed a pact with Quad Technologies, a Woburn, Massachusetts-based biotechnology company that specializes in cell- separation technologies.

This partnership is expected to enable worldwide availability of a magnetic bead-free T cell activation product built with Quad Technologies’ patented QuickGel platform for cell-therapy manufacturing.

The deal covers a brand new QuickGel-based product that enables CD3 and CD28-mediated T cell activation, which is expected to begin shipping in 2018 in both in-research and cGMP grades.

Source: Quad Technologies